有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Aprepitant;MK-869;MK-0869;L-754030;Emend
Chemical Name 5-[2(R)-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2H-1,2,4-triazol-3-one
CAS 170729-80-3
Related CAS 170902-81-5 ((1S)-isomer), 221350-96-5 (deleted CAS), 172822-28-5 (stereoisomer), 172822-29-6 (ster
Formula C23H21F7N4O3
Structure
Formula Weight 534.43762
Stage 上市-2003
Company Merck & Co. (Originator)
Activity/Mechanism Antidepressants, Mood Disorders, Treatment of, Nausea and Vomiting, Treatment of, NEUROLOGIC DRUGS, PSYCHOPHARMACOLOGIC DRUGS, Tachykinin NK1 Antagonists
Syn. Route 4
Route 1
reduction of morpholinone (i) with l-selectride in thf at -78 c produced the intermediate lactol (ii), which was condensed at low temperature with 3,5-bis(trifluoromethyl)benzoyl chloride (iii) to afford acyl acetal (iv). further reaction with dimethyl titanocene in thf-toluene at 80 c provided enol ether (v). catalytic hydrogenation of the double bond, with concomitant n-benzyl group hydrogenolysis, yielded a 8:1 mixture of diastereomers, from which the major isomer (vi) was isolated by column chromatography. alkylation of morpholine (vi) with n-methoxycarbonyl-2-chloroacetamidrazone (vii) (obtained by reaction of chloroacetonitrile (ix) with naome and methyl carbazate in meoh) in the presence of n-ethyl diisopropylamine (diea) in acetonitrile gave the intermediate (viii), which was finally cyclized to the desired triazolone in refluxing xylene.
List of intermediates No.
(1r,5s,6s)-6-(1(r)-hydroxyethyl)-2-[1,1-dimethyl-5(s)-[4-(4-nitrobenzyloxycarbonyl)piperazin-1-ylcarbonyl]pyrrrolidinium-3(s)-ylsulfanyl]-1-methyl-1-carba-2-penem-3-carboxylic acid 4-nitrobenzyl ester fluorosulfonate; (1r,5s,6s)-6-(1(r)-hydroxyethyl)-2-[1,1-dimethyl-5(s)-[4-(4-nitrobenzyloxycarbonyl)piperazin-1-ylcarbonyl]pyrrrolidinium-3(s)-ylsulfanyl]-1-methyl-1-carba-2-penem-3-carboxylic acid 4-nitrobenzyl ester fluorosulfonate (ix)
isopropyl isocyanate; 2-isocyanatopropane (i)
Reference 1:
    castaner, j.; silvestre, j.s.; bayes, m.; sorbera, l.a.; aprepitant and l-758298. drugs fut 2002, 27, 3, 211.
Reference 2:
    cowden, c.j.; et al.; a new synthesis of 1,2,4-triazolin-5-ones: application to the convergent synthesis of an nk1 antagonist. tetrahedron lett 2000, 41, 44, 8661.
Reference 4:
    dorn, c.p.; hale, j.j.; maccoss, m.; mills, s.g.; ladduwahetty, t.; shah, s.k. (merck & co., inc.); morpholine and thiomorpholine tachykinin receptor antagonists. ep 0577394; jp 1994172178; us 5719147; wo 9400440; wo 9516679 .
Reference 5:
    dorn, c.p.; hale, j.j.; maccoss, m.; mills, s.g. (merck & co., inc.); prodrugs of morpholine tachykinin receptor antagonists. ep 0748320; jp 1997509935; us 5691336; wo 9523798 .
Reference 6:
    maccoss, m.; hale, j.j.; mills, s.g.; et al.; phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. j med chem 2000, 43, 6, 1234.
Reference 7:
    dolling, u.h.; wilson, r.d.; hands, d.; cottrell, i.f. (merck sharp & dohme ltd.); chemical synthesis of morpholine derivs.. wo 9965900 .
Reference 8:
    cowden, c.j. (merck sharp & dohme ltd.); process for the preparation of 1,2,4-triazolin-5-one derivs.. wo 0196315 .
Reference 3:
    hale, j.j.; mills, s.g.; maccoss, m.; finke, p.e.; cascieri, m.a.; sadowski, s.; ber, e.; chicchi, g.g.; kurtz, m.; metzger, j.; eiermann, g.; tsou, n.n.; tattersall, f.d.; rupniak, n.m.; williams, a.r.; rycroft, w.; hargreaves, r.; macintyre, d.e.; structural optimization affording 2-(r)-(1-(r)-3,5-bis(trifluoromethyl)phenylethoxy)-3(s)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human nk-1 receptor antagonist. j med chem 1998, 41, 23, 4607.

Route 2
synthesis of morpholine intermediate (i): treatment of 4-fluorophenyl acetic acid (x) with trimethylacetyl chloride (xi) and et3n in et2o followed by reaction with 4-(s)-benzyl-2-oxazolidinone (xii) in thf and n-buli in hexane affords oxazolidinone derivative (xiii). conversion of (xiii) into azido derivative (xv) is achieved by first treatment of (xiii) in thf with a potassium bis(trimethylsilyl)amide solution in toluene followed by treatment with 2,4,6-triisopropylphenylsulfonyl azide (xiv) in thf. hydrolysis of azido-oxazolidinone derivative (xv) by means of lioh in thf/h2o yields azido acetic acid derivative (xvi), which is then hydrogenated over pd/c in h2o/hoac to afford (s)-(4-fluorophenyl)glycine (xvii). treatment of (s)-(4-fluorophenyl)glycine (xvii) with benzaldehyde (xviii), naoh and nabh4 in meoh yields n-benzyl (s)-(4-fluorophenyl)glycine (xix), which is then cyclized with 1,2-dibromoethane (xx) in the presence of diea in dmf to furnish morpholine intermediate (i).
List of intermediates No.
ethyl 2-[2-([[(4-chlorophenyl)sulfonyl]amino]methyl)-2,3-dihydro-1h-inden-5-yl]-2-(methylsulfanyl)acetate (xx)
methyl 3-[5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1h-thieno[2,3-e][1,4]diazepin-7-yl]propanoate (xviii)
3-sulfanyl-1-propanol (xi)
(3as,4r,8r,8as)-4,8-dibenzyl-2,2-dimethylhexahydro-6h-[1,3]dioxolo[4,5-e][1,3]diazepin-6-one (xii)
isopropyl isocyanate; 2-isocyanatopropane (i)
1-azabicyclo[1.1.0]butane (x)
tert-butyl (2s,4r)-2-[(dimethylamino)carbonyl]-4-hydroxy-1-pyrrolidinecarboxylate (xvii)
2-(1-hydroxyethylidene)-5,5-dimethyl-1,3-cyclohexanedione (xiii)
(2s)-1-{2-[(2-{[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]amino}ethyl)amino]acetyl}-2-pyrrolidinecarboxamide (xiv)
tert-butyl 2-[(2s)-2-(aminocarbonyl)pyrrolidinyl]-2-oxoethyl(2-{[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]amino}ethyl)carbamate (xv)
tert-butyl 2-[(2s)-2-(aminocarbonyl)pyrrolidinyl]-2-oxoethyl(2-aminoethyl)carbamate (xvi)
tert-butyl 2-[(2s)-2-(aminocarbonyl)pyrrolidinyl]-2-oxoethyl{2-[(5-cyano-2-pyridinyl)amino]ethyl}carbamate (xix)
Reference 1:
    castaner, j.; silvestre, j.s.; bayes, m.; sorbera, l.a.; aprepitant and l-758298. drugs fut 2002, 27, 3, 211.
Reference 2:
    dorn, c.p.; hale, j.j.; maccoss, m.; mills, s.g. (merck & co., inc.); prodrugs of morpholine tachykinin receptor antagonists. ep 0748320; jp 1997509935; us 5691336; wo 9523798 .
Reference 3:
    dorn, c.p.; hale, j.j.; maccoss, m.; mills, s.g.; ladduwahetty, t.; shah, s.k. (merck & co., inc.); morpholine and thiomorpholine tachykinin receptor antagonists. ep 0577394; jp 1994172178; us 5719147; wo 9400440; wo 9516679 .

Route 3
alternatively (xvii) can be obtained as follows: reaction of 4-fluorophenyl acetic (x) with thionyl chloride in toluene in the presence of dmf provides 4-fluorophenyl acetyl chloride (xxii), which is treated with bromine and light irradiation followed by reaction with methanol to furnish methyl bromoacetate derivative (xxiii). treatment of (xxiii) with benzyl triethylammonium chloride (xxiv) and nan3 in meoh followed by hydrogenation over pd/c in meoh gives methyl glycine derivative (xxv) in a racemic mixture, from which (xvii) is obtained by crystallization of the corresponding dibenzoyl tartaric (dbt) salts followed by salt hydrolysis by means of refluxing hcl.
List of intermediates No.
1-azabicyclo[1.1.0]butane (x)
3-tetrahydro-2h-thiopyran-2-ylpyridine (xxiv)
(6r,7r)-7-[[2-[2-([(2s)-2-[(tert-butoxycarbonyl)amino]propanoyl]amino)-1,3-thiazol-4-yl]-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (xxii)
tert-butyl (2s,4r)-2-[(dimethylamino)carbonyl]-4-hydroxy-1-pyrrolidinecarboxylate (xvii)
n-{2-[(5-cyano-2-pyridinyl)amino]ethyl}-n-{2-[(2s)-2-cyanopyrrolidinyl]-2-oxoethyl}-2,2,2-trifluoroacetamide (xxiii)
r(-)-1-phenyl-1,2-ethanediolr(-)-phenylethylene glycol (xxv)
Reference 1:
    castaner, j.; silvestre, j.s.; bayes, m.; sorbera, l.a.; aprepitant and l-758298. drugs fut 2002, 27, 3, 211.
Reference 2:
    dorn, c.p.; hale, j.j.; maccoss, m.; mills, s.g. (merck & co., inc.); prodrugs of morpholine tachykinin receptor antagonists. ep 0748320; jp 1997509935; us 5691336; wo 9523798 .
Reference 3:
    dorn, c.p.; hale, j.j.; maccoss, m.; mills, s.g.; ladduwahetty, t.; shah, s.k. (merck & co., inc.); morpholine and thiomorpholine tachykinin receptor antagonists. ep 0577394; jp 1994172178; us 5719147; wo 9400440; wo 9516679 .

Route 4
synthesis of 250157: alternatively, the final compound can be obtained by direct condensation of (vi) with chlorotriazolinone (xxvi) in dmf/h2o in the presence of k2co3 or diea.for the obtention of (xxvi), two routes can be followed: 1. reaction of semicarbazide (xxvii) with orthoester (xxviii) in meoh; and 2. condensation of semicarbazide (xxvii) with benzyloxyacetyl chloride (xxix) in thf/h2o in the presence of naoh to provide adduct (xxx), which is then cyclized by means of refluxing naoh to afford triazolinone (xxxi). debenzylation of (xxxi) by hydrogenation over pd/c in meoh/h2o yields alcohol (xxxii), which is finally treated with thionyl chloride.
List of intermediates No.
diethyl 2-(3-oxopropyl)malonate (xxix)
ethyl (e)-3-(2-furyl)-2-propenoate (vi)
(2s)-2-hydroxy-2-phenylethyl 4-methylbenzenesulfonate (xxvii)
(3r)-3-hydroxy-3-phenylpropanenitrile (xxx)
(1r)-3-amino-1-phenyl-1-propanol (xxxi)
(3r)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine; (3r)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine (xxxii)
methyl (3r)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylcarbamate (xxvi)
Reference 1:
    castaner, j.; silvestre, j.s.; bayes, m.; sorbera, l.a.; aprepitant and l-758298. drugs fut 2002, 27, 3, 211.
Reference 2:
    cowden, c.j.; et al.; a new synthesis of 1,2,4-triazolin-5-ones: application to the convergent synthesis of an nk1 antagonist. tetrahedron lett 2000, 41, 44, 8661.
Reference 3:
    cowden, c.j. (merck sharp & dohme ltd.); process for the preparation of 1,2,4-triazolin-5-one derivs.. wo 0196315 .
Reference 4:
    dolling, u.h.; wilson, r.d.; hands, d.; cottrell, i.f. (merck sharp & dohme ltd.); chemical synthesis of morpholine derivs.. wo 9965900 .

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名阿瑞吡坦;英文名Aprepitant;MK-869;MK-0869;L-754030;Emend;CAS[170729-80-3]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
唐山盛源泽兴化工有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
因抗药性,这些农药已失效了,怎
当前我国小麦主要病虫害发生面积
2019年农药市场谁主沉浮?
必须知道!这些问题在农药登记申
用药拌干稻种可减轻恶苗病和干尖
检察机关:农资打假绝不手软!
这29条环境违法行为可举报!奖
安道麦推出新产品,并将致力于完
原药登记中环境试验项目:环境归
2018年我国农药发展回顾与对
具有应用前景的新型杀线虫剂
涉及21家农化企业,山东省公布
联化科技2019年第一季度净利
2018年我国农药标准发布概况
山东省农作物病虫预报:小麦/玉
草甘膦再评审即将开始!欧盟提议
偷排废液2650吨!公司被罚款
十大典型!2018年共挽回1.
农业农村部×中化集团:携手共促
重磅!2019年全球化工企业5
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明